Peter Nash (@drpnash) profile picture

Rheumo, Golfer(pathetic), Caravaggisti, Prof School of Medicine Griffith University, A/Prof Univ. of Qld, Director Rheumatology Research Unit Sunshine Coast,

Sunshine Coast
Joined December 2011
Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)Photo by Peter Nash (@drpnash)
Raff - Creative - lipid nanoparticle delivery APLAR Seoul 2026 #CART #RheumNow
2
80
Chan Hong Kong prediction CRS 80/20 - 80% CRS 20% hypoxia hypotension etc predictors 4 groups b cell load and IL6 level APLAR Seoul 2026 #CART #RheumNow
50
Schett - relapse rates different imids 14.5% APLAR Seoul 2026 #CART #RheumNow
1
61
Schett - in remission : 14 normal pregnancies no SLE recurrence , babies normal b cells APLAR Seoul 2026 #CART #RheumNow
2
46
Schett : in vivo the future if it works, during LD aciclovir, co-trimoxazole, CAR-T expansion amount not associated with toxicity, 3 month no vaccination window, all tissues B cell depletion , naive b cells return APLAR Seoul 2026 #CART #RheumNow
55
Georg Schett : cure prime goal of therapy! remission off all treatment , APLAR Seoul 2026 #CART #RheumNow
48
ExVivo advantages APLAR Seoul 2026 #CART #RheumNow
3
161
lymphodepletion depends on individual cytokine profile and fludarabine PK effects efficacy APLAR Seoul 2026 #CAR-T #Rheum Now
35
number of naive-like CAR-T infused associates with prolonged survival but highly variable APLAR Seoul 2026 #CAR-T #Rheum Now
44
Prof Cam Turtle,Sydney, ex-vivo CAR-T for oncology - 2-6 wk wait for expansion problematic, no CRS unlikely ICANS, APLAR Seoul 2026 #CAR-T #RheumNow
2
40
CAR-T cell therapy - hottest topic in autoimmune disease - symposium APLAR Seoul 2026 #CAR-T #RheumNow
2
92